Skip to main content
Clinical Trials/JPRN-UMIN000018868
JPRN-UMIN000018868
Recruiting
未知

Anti-inflammatory and immunomodulative effects of human recombinant thrombomodulin for severe septic patients - Anti-inflammatory and immunomodulative effects of human recombinant thrombomodulin

Inoue's Labo in Tokai University0 sites45 target enrollmentAugust 31, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Inoue's Labo in Tokai University
Enrollment
45
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 31, 2015
End Date
March 31, 2016
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Inoue's Labo in Tokai University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Anti-inflammatory and immunomodulative effects of clarithromycin for severe septic patientssevere sepsis
JPRN-UMIN000021476Inoue laboratory, Tokai University30
Active, not recruiting
Phase 1
Investigation of the anti-inflammatory effects of simvastatin in a model of acute lung injury after inhalation of lipopolysaccharide by healthy volunteers - Statins in a model of acute lung injury in healthy volunteersAcute lung injury (ALI)
EUCTR2006-004396-35-GBBelfast City Hospital Trust
Completed
Not Applicable
Investigation of the anti-inflammatory effects of simvastatin in a human lipopolysaccharide induced model of acute lung injury
ISRCTN21056528Belfast Health and Social Care Trust (UK)30
Active, not recruiting
Not Applicable
Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patientsMetastatic Cutaneous and Subcutaneous MelanomaMedDRA version: 15.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-002059-40-ITISTITUTO NAZIONALE PER LA CURA TUMORI
Active, not recruiting
Phase 1
Own mesenchymal stem cells for multiple sclerosis patientsMultiple sclerosisMedDRA version: 18.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-000518-13-DKProf. Per Soelberg Sørensen